Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission

被引：0

作者：

Cohen, Adam D. ^{[1
]}

Garfall, Alfred L. ^{[2
]}

Susanibar-Adaniya, Sandra Patricia ^{[2
]}

Vogl, Dan T. ^{[2
]}

Waxman, Adam ^{[2
]}

De Mesa, Oksana ^{[2
]}

Kane, Elizabeth ^{[3
]}

Nichols, Charles ^{[4
]}

Razzo, Beatrice ^{[2
]}

Stadtmauer, Edward A. ^{[2
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

653

引用

页码：12628 / 12629

页数：2

共 50 条

[1] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: the phase 1/2 BelaRd study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S103 - S103
[2] Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma
Shah, Jatin J.
Baladandayuthapani, Veera
Weber, Donna M.
Thomas, Sheeba K.
Alexanian, Raymond
Wang, Michael
Qazilbash, Muzaffar H.
Champlin, Richard E.
Shah, Nina
Bashir, Qaiser
Popat, Uday R.
Nieto, Yago
Ahmed, Sairah
Parmar, Simrit
Orlowski, Robert Z.
BLOOD, 2013, 122 (21)
[3] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kostopoulos, Ioannis V.
Syrigou, Rodanthi-Eleni
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Tsitsilonis, Ourania E.
Kastritis, Efstathios
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605
[4] How To Effectively Administer Belantamab Mafodotin: Knowledge Gained From the Phase 1/2 BelaRd Study in Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kanellias, Nikolaos
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Psarros, Giorgos
Antoniou, Nasia
Douvali, Maria
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S199 - S199
[5] Renal safety evaluation of zoledronic acid and thalidomide when used as post-stem cell transplant maintenance therapy in multiple myeloma
Spencer, A
Roberts, A
Neeman, T
Schran, H
Lynch, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 596S - 596S
[6] DREAMM-9: Phase I Study of Belantamab Mafodotin with Standard of Care in non-transplant-eligible Patients with newly diagnosed multiple Myeloma
Raab, M. S.
Usmani, S. Z.
Mielnik, M.
Koh, Y.
Alonso Alonso, A.
Leleu, X.
Quach, H.
Min, C-K.
Janowski, W.
Abdallah, A. -O.
Garg, M.
Sandhu, I.
San Miguel, Ocio E. M.
Oriol, A.
Rodriguez-Otero, P.
Ramasamy, K.
Weisel, K.
Besemer, B.
Cavo, M.
Zhou, X. L.
Kaisermann, M. C.
Bego Marques, C. M.
Williams, D.
Carreno, F.
Kremer, B. E.
Gupta, I. V.
Hus, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 145 - 146
[7] Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Roussou, Maria
Psarros, Giorgos
Kastritis, Efstathios
Dimopoulos, Meletios A.
Terpos, Evangelos
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 502 - 504
[8] Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Syrigou, Rodanthi
Papaiakovou, Evangelos Eleutherakis
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Preliminary Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Thomas, Sheeba K.
Shah, Jatin J.
Lee, Hans C.
Manasanch, Elisabet E.
Weber, Donna M.
Patel, Krina K.
Feng, Lei
Amini, Behrang
Morphey, Ashley
Crumpton, Brandon
Phillips, Suzanne
Miller, Carla
Gonzalez, Mariann
Orlowski, Robert Z.
BLOOD, 2017, 130
[10] Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Shah, Jatin J.
Feng, Lei
Weber, Donna
Thomas, Sheeba K.
Wang, Michael
Turturro, Francesco
Qazilbash, Muzaffar H.
Shah, Nina
Bashir, Qaiser
Popat, Uday R.
Manasanch, Elisabet E.
Munoz, Silvia C.
Landry, Ashley
Mendoza, Kathleen
Nieto, Yago
Champlin, Richard E.
Orlowski, Robert Z.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →